A abstinência no alcoolismo. Comportamento da transferrina deficiente em carbo-hidratos (CDT)
Palavras-chave:
alcoolismo, abstinência, transferrina deficiente em carbo-hidratos, status do ferroResumo
Presentemente, a transferrina deficiente em carbo-hidratos -(CDT) é o marcador biológico acessível mais apropriado na discriminação do consumo persistente de álcool.
Um grupo de 55 doentes álcool-dependentes, internados para tratamento e recuperação no Centro Regional de Alcoologia de Lisboa, após 4 semanas de abstinência controlada, vem a sofrer quebras significativas dos níveis médios de transferrina anormal No entanto, nesta condição, permanecem ainda frequências deste marcador mais elevadas que os níveis de referência convencionais, nomeadamente nos álcool-dependentes com infecção virai (VHB, VHC). Estas frequências vêm a ser, contudo, bem inferiores às frequências anormais dos marcadores tradicionais (AST/ALT/GGT) de álcool-dependentes sob abstinência, nomeadamente naqueles com infecção vira o que vem a revelar a sua melhor especificidade no alcoolismo/ abstinência. Também as frequências de índices anormais do status do ferro são mais elevadas nos álcool-dependentes sob abstinência, nomeadamente com infecção viral que na população referência, sendo útil a apreciação crítica de níveis de transferrina por esta se correlacionar com as suas isoformas indu zidas pelo álcool.
Os dados aconselham a necessidade da de terminação dos níveis de transferrina anormal no álcool-dependente sob abstinência controlada, que deverá ser o valor de referência individual na vigilância subsequente de manutenção da ausência de consumos.
Downloads
Referências
Stibler H. Carbohydrate-deficient Transferrin in scrum: a new marker of potentially harmful alcohol consumption reviewed. Clin Chem 1991; 37: 2029-2037.
Allen JP, Litten RZ, Anton RF, Gross GM. Carhohydrate - deficient Transferrin as a measure of immoderate drinking: remaining issues. Alcohol Clin Exp Res 1994; 18: 799-812.
Sillanaukee P. Laboratory markers of alcohol abuse . Al cohol Alcohol 1996; 31: 613-616.
Wetterling T, Kanitz RD. Clinical value of laboratory findings in alcoholics. Eur Addict Res 1996; 2: 140-146.
Meerkerk GJ. CDT in general practice. Alcohol Alcohol 1997; 32:312 S.
Fanske S. The use of CDT in primary health care. Alcohol Alcohol 1997; 32:314 S.
Sillanaukee P, Aalto M. Prevalence and detection of heavy drinking among primary health care patients - experience from the Lakti Brief Intervention Study. Alcohol Alcohol 1997; 32:319 S.
Borg S, Helander A, Carlsson AV, et ai. Detection of relapses in alcohol dependent patients using carbohydrate-de ficient transferrin: improvernent with individualized refe rence leveis during long-term monitoring. Alcohol Clin Exp Res 1995;19:961-963.
Helander A, Carlsson AV. Borg S. Longitudinal comparison of CDT anel GGT leveis in alcohol dependent subjects. Alcohol Alcohol 1995; 30:557.
Anton RF, Moak DH, Lathan PK. Carbohydrate-deficient Transferrin (CDT) as a marker for relapse drinking in a pharmacologic treatment study of alcohol dependence. Alcohol Clin Exp Res 1995; 19 :43 A.
Decrey H, Fellrath F, Van Melle G, et al. l'sefulness of carbohvdrate-deficient transferrin in follow-up after alcohol withdrawal. Alcohol Alcohol 1995; 30:555'.
Rosman AS, Basul P, Gavin K, Lieber CS. Utility of carbo hydrate-deficient transferrin as a marker of relapse in alcoholic patients. Alcohol Clin Exp Res 1995; 19:611-616.
Anton RF. Toe use of carhnhydrate-deficient transferrin as an indicator of alcohol consumption during treatment and follow-up. Alcohol Clin Exp Res 1996; 20:5·4'-56'
De Jong G, van Dijk JP, van Eijk HG. The biology of transferrin. Clin Chem Acta, 1990; 190:1-46.
Durand G. Overview on pathological glycosilation. Al cohol Alcohol 1997; 32:310S.
Bean P, Peler JP. Allelic D. Variants of transferrin in evaluation of alcohol abuse: differential diagnosis by isoelectric focusing-immunobloting-laser densitometry. Clin Chem 1994; 40: 2078-2083.
Xin y, Lasker J, Lieber CS. Serum carbohydrate-deficient transferrin: mechanism of increase after chronic alcohol intake. Hepatology 1995; 22: 1462-1468.
Bell H, Talleksen C, Sjahcim T, et al. Serum carbohydrate-deficient transferrin with chronic liver diseases. Alcohol Clin Exp Res 1993; 17: 246-252.
Caldwell SH, Hallyday JW, Fletcher LM. carbohydrate deficient transferrin in alcoholics with liver disease. J Gastroent anel Hepat 1995; 10: 174-178.
Niemela O, Sorvajarvi K. Blake JE, Israel Y. Carbohyelra te-eleficient transferrin as a marker of alcohol abuse: relationship to alcohol consumption, severity of liver disease, and fibrogenesis. Alcohol Clin Exp Res 1995; 19: 1203-1208.
Niemela O, Sorvajarvi K, Blake JE, Israel Y. Relationship of carbohydrate-deficient transferrin to the severity of alcoholic liver disease. Alcohol Alcohol 1995; 30: 561.
Bell, Heller K, Harthing S et al. Different levels of serum carbohydrate-deficient transferrin (CDT) in chronic hepatitis C and haemochromatosis. Alcohol Alcohol 1995; 30: 555'.
Sorvajarvi K, Blake JE, Israel Y et al. Sensitivity and specificity of carbohydrate deficient transferrin as a marker of alcohol abuse are significantly influenced by alterations in serum transferrin: comparison of two methods. Alcohol Clin Exp Res 1996; 20 : 449-454.
Bell H, Tallaksen ME, Try K, Hang E. Carbohydrate-defi cient transferrin and other markers of high alcohol comsumption: a study of 502 patients admitted consecutively to a medical department. Alcohol Clin Exp Res 1994, 18: 1103-1108.
Yamauchi M, Hirakawa J, Maezawa Y et al. Serum level of carbohydrate-deficient transferrin as a marker of alcoholic liver disease Alcohol Alcohol 1993; 28: 3-8.
Gordon HM, SherWood R, Morgan MY. Serum carbo hydrate-deficient transferrin (CDT) comparison of methodologies. Alcohol Alcohol 1997; 32: 331 S.
Rommelspacher H, Spies C, Schmidt K. Laboratory marker monitoring in na intensive care unit and in a long term rehabilitation program. Alcohol Alcohol 1995; 30: 492A.
Bell H, Skimingsrud A, Raknerud N, Try K. Semm ferritin and transferrin saturation in patients with chronic alcoholic and non-alcoholic liver diseases. J Intern Med 1994; 236: 315-322.
Vernet M, Bried A, Simplot A. Metabolisme du fer et infection à VIH: étude préliminaire. Ann Biol Clin 1997; 55: 477-480.
Weinberg ED. Irem witholding: a defence against viral infections. Bio Metais 1996; 9: 393-399.
Moirand R, Lescoat G, Delamaire D et ai. Increase in glucosylated and nonglycosylated serum ferritin in chronic alcoholism and their evolution during alcohol withdrawall. Alcohol Clin Exp Res 1991; 15: 963-969
Lee MH, Means RT. Extremely elevated serum ferritin levels in a University hospital: associated diseases and Clinical Significance. Am J Medicine 1995; 98: 566-571.
Grossard AA, Gross JR, Burgaret LJ et al. Significance of iron indices in hepatitis C, alcoholic liver diseases, and non-C, non-alcoholic liver disease. Gastroenterol 1995; 108: A 1075.
Bronkovsky H, Banner BF, Rothman AL. Iron and chronic viral hepatitis..Hepatology 1997; 25: 759-768.
Dibisceglie AM, Axiotis CA, Hoofnagle JB, Bacon BR. Measurements of iron status in patients with chronic hepatitis. Gastroenterol 1992; 102: 2108-2113.
Potter BJ, Chapman RWG, Nunes RM. et al. Transferrin metabolism in alcoholic liver disease. Hepatology 1985; 5: 714-721.
Bedossa P, Poynard T, Abella et al. Apolipoprotein A1 is a serum and tissue marker of liver fibrosis in alcoholics patients. Alcohol Clin Exp Res 1989; 13: 829-833.
Poynard T, Aubert A, Bedossa P et al. A simple biological index for detection of alcoholic liver disease in drinkers. Gastroenterol 1991; 100: 1397-1402.
Paradis V, Mathurin P, Ratziu V et al. Binding of Apolipoprotein A1 and acetaldehycle-modified Apolipoprotein A1 to liver extracellular matrix. Hepatology 1996; 23: 1232-1238.
Poynard T, Abella A, Pignon JP et al. Apolipoprotein A1 and alcoholic liver disease. Hepatology 1987; 6: 1391-
Mathurin P, Viclaut D, Bedossa P et al. Quantification of apolipoprotein A1 anel B messenger RNA in heavy drinkers according to liver disease. Hepatology 1996; 23: 44-51.
Peneda JA, Fonseca A, Neves M et al. Asialo-Transferrina discriminante do consumo excessivo activo de álcool, subagudo e crónico - Utilidade clínica na doença hepática. Acta Médica 1996; 9: 103-111.
Van Lceuwen DJ, Wilson L, Crowe DR. Liver biopsy in the mid 1990's: questions and answers. Sem Liver Dis 1995; 15: 340-359.
Ficheiros Adicionais
Publicado
Como Citar
Edição
Secção
Licença
Este trabalho encontra-se publicado com a Licença Internacional Creative Commons Atribuição 4.0.
Direitos de Autor (c) 2023 Medicina Interna
Acesso livre
